Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$19.59 0.40 (2.08%)
2/9/2010 4:00 PM

Crucell N.V. (ADR) (CRXL)

CAPS Rating:
****

A fully integrated biopharmaceutical company, focuses on developing, producing and marketing vaccines and antibodies against infectious diseases for private and public markets worldwide and leverage its novel, proprietary technologies.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating CRXL

Add Stock to Watchlist

What the Community Thinks

Total Members

120 Outperforms
7 Underperforms
 

All-Stars

33 Outperforms
3 Underperforms
 

Wall Street

2 Outperforms
0 Underperforms
 

Members bullish on CRXL are also bullish on:

Members bearish on CRXL are also bearish on:

Ticker Tags

International Stock (684), Value (1901), Defensive (1457), Biotechnology (220), Small Cap (1645), Netherlands (15), Healthcare (711)
Suggest a tag

Crucell N.V. (ADR) At A Glance

Current Price: $19.59
Last Trade Time: 2/9/2010 4:00 PM
Open: $19.06
Previous Close: $19.19
Daily Range: $19.06 - $19.65
52-Week Range: $17.50 - $25.53
Volume: 157,578
Market Cap: $1.30B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CRXL VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Crucell N.V. (ADR) (CRXL)

Avatar delavida (< 20) Submitted: 10/17/09 10:02 AM

Crucell is involved in every major vaccine program in the world including TB, malaria, HIV and ebola. In addition with it proprietary technology including PERc.6, AdVac and MabAbstract they are miles ahead of competitors. In addition with over 80 partners having clinical trials underway the royalt...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Crucell N.V. (ADR) (CRXL)

Avatar brendatucker (< 20) Submitted: 7/10/08 11:25 PM

Do we really need another supplier of vaccines?

Avid Bioservices in California has contracted to distribute the vaccines, but Avid is owned by Peregrine (PPHM) a company whose stock is trading under $1. The most that can be hoped for with Avid's assistance (distribute and produce) and customer bas...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 24 :   1 2 3 4 5 Next »

Recs

0

 (CRXL)

Avatar grapesharvester (< 20) Submitted: 1/05/10 6:02 PM : Outperform Start Price: $20.61 CRXL Score: 0.60

patents will pay off.
several new products in pielline will reach the market within 5 years.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRXL)

Avatar PoorUnemployed (< 20) Submitted: 10/23/09 9:28 AM : Outperform Start Price: $21.31 CRXL Score: -5.82

CRXL has some of the best technology for making vaccines. Guess what? This is the era of vaccines! You hear about it everyday in the media. Target $28.00

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (CRXL)

Avatar delavida (< 20) Submitted: 10/17/09 10:02 AM : Outperform Start Price: $21.36 CRXL Score: -6.59

Crucell is involved in every major vaccine program in the world including TB, malaria, HIV and ebola. In addition with it proprietary technology including PERc.6, AdVac and MabAbstract they are miles ahead of competitors. In addition with over 80 partners having clinical trials underway the royalty income should be substantial within the next 5 years. With the US government support and recent partnership with JNJ Crucell ,may turn the Flu vaccine business totally around with their Universal flu antibody and a possible universal flu vaccine. The company is grossly undervalues and under the radar and presently has over 600 million in cash

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (CRXL)

Avatar andcheese (67.92) Submitted: 9/04/09 2:50 PM : Outperform Start Price: $22.02 CRXL Score: -16.74

Crucell, the seventh-largest vaccine maker in the world, sells the flu vaccine Inflexal. Mild flu seasons over the last two years have made it difficult for Crucell to grow its flu vaccine franchise. But if advance orders from competing firms are any indication, Crucell could increase its seasonal flu vaccine sales by at least 50% this year. That could translate to an extra, unexpected $40 million in revenue. For a firm with about $400 million in sales, that's no chump change.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRXL)

Avatar zircom (< 20) Submitted: 7/21/09 7:07 PM : Outperform Start Price: $24.29 CRXL Score: -32.79

Crucell has shown strong growth this year compared to the biopharmaceutical industry as a whole and doesn’t seem to be slowing down with strong financials and a good debt to equity ratio.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 24 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackUBS 87.99 11/06/09 Outperform NS $21.22-7.68%+1.48%-9.16
TrackNeedham 67.64 11/14/07 Outperform NS $19.07+2.73%-24.72%+27.45

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 343ms